Immunofluorescence (IF) is an immunochemical staining technique that utilizes fluorochrome-labeled antibodies for the visualization and localization of targets, by labelling with a fluorescent dye such as fluorescein isothiocyanate (FITC). It can identify a wide range of components on tissue sections, cultured cells, or individual cells, and is thus highly valuable for their broad capability with the use of combinations of specific antibodies tagged with fluorophores.
There are several steps for IF, with the first being fixation to immobilize target antigens while maintaining cellular architecture. Next, sample preparation and blocking needs to be carried out to prevent non-specific binding of antibodies. Then, incubation of primary and secondary antibodies take place before the final preservation and imaging.
There are two different IF methods available: Direct (Primary) and Indirect (Secondary). Direct detection requires using a single fluorochrome-conjugated primary antibody. Meanwhile, indirect detection uses two antibodies, with the first being an unlabeled primary antibody, followed by a fluorochrome-conjugated secondary antibody.
Although both monoclonal and polyclonal antibodies can be used for IF, they have their own pros and cons. Indirect IF more commonly used as the secondary antibodies are typically polyclonal, allowing for the recognition of multiple epitopes of the targets. However, monoclonal antibodies which are specifically designed for IF may be more preferable if your research involves recognizing very specific targets.1
At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Im, K., Mareninov, S., Diaz, M. F. P., & Yong, W. H. (2019). An introduction to Performing Immunofluorescence Staining. Methods in Molecular Biology (Clifton, N.J.), 1897, 299. https://doi.org/10.1007/978-1-4939-8935-5_26
The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.
Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.
Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.
Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.
ScientistとScience Exchangeとのご利用可能です。
